MX381187B - Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. - Google Patents

Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.

Info

Publication number
MX381187B
MX381187B MX2017010506A MX2017010506A MX381187B MX 381187 B MX381187 B MX 381187B MX 2017010506 A MX2017010506 A MX 2017010506A MX 2017010506 A MX2017010506 A MX 2017010506A MX 381187 B MX381187 B MX 381187B
Authority
MX
Mexico
Prior art keywords
quinoline derivative
prevention
treatment
viral infections
present
Prior art date
Application number
MX2017010506A
Other languages
English (en)
Other versions
MX2017010506A (es
Inventor
Aude Garcel
Audrey Vautrin
Didier Scherrer
Florence Mahuteau
Jamal Tazi
Noëlie Campos
Pauline Fornarelli
Romain Najman
Original Assignee
Abivax
Centre Nat Rech Scient
Inst Curie
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax, Centre Nat Rech Scient, Inst Curie, Univ Montpellier filed Critical Abivax
Publication of MX2017010506A publication Critical patent/MX2017010506A/es
Publication of MX381187B publication Critical patent/MX381187B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un derivado de quinoleína de la fórmula (1) o una de sus sales farmacéuticamente aceptables. La presente invención se refiere además al derivado de quinoleína para el medicamento y para su uso en el tratamiento o prevención de una infección viral o retroviral y en particular el SIDA o una afección relacionada con el SIDA o el virus de inmunodeficiencia humana (VIH). La presente invención se refiere también a una composición farmacéutica que comprende el derivado de quinoleína y al proceso para prepararla como un nuevo compuesto intermedio.
MX2017010506A 2015-02-23 2016-02-19 Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. MX381187B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305274.1A EP3059236A1 (en) 2015-02-23 2015-02-23 A new quinoline derivative for use in the treatment and prevention of viral infections
PCT/EP2016/053532 WO2016135052A1 (en) 2015-02-23 2016-02-19 A new quinoline derivative for use in the treatment and prevention of viral infections

Publications (2)

Publication Number Publication Date
MX2017010506A MX2017010506A (es) 2017-11-13
MX381187B true MX381187B (es) 2025-03-12

Family

ID=52629497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010506A MX381187B (es) 2015-02-23 2016-02-19 Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.

Country Status (22)

Country Link
US (1) US10329317B2 (es)
EP (2) EP3059236A1 (es)
JP (1) JP6797126B2 (es)
KR (1) KR102583506B1 (es)
CN (1) CN107531681B (es)
AU (1) AU2016223687B2 (es)
BR (1) BR112017017500B1 (es)
CA (1) CA2975577C (es)
CU (1) CU24525B1 (es)
DK (1) DK3262037T3 (es)
ES (1) ES2785374T3 (es)
HR (1) HRP20200649T1 (es)
HU (1) HUE048577T2 (es)
LT (1) LT3262037T (es)
MX (1) MX381187B (es)
PL (1) PL3262037T3 (es)
PT (1) PT3262037T (es)
RS (1) RS60369B1 (es)
RU (1) RU2723013C2 (es)
SI (1) SI3262037T1 (es)
WO (1) WO2016135052A1 (es)
ZA (1) ZA201705633B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
US20190034990A1 (en) * 2017-07-26 2019-01-31 International Business Machines Corporation Information insight system for providers of products or services
EP3669873A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3669874A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
EP3881844A1 (en) * 2020-03-20 2021-09-22 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
BR112022018793A2 (pt) * 2020-03-20 2022-11-29 Abivax Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae
EP3884946A1 (en) * 2020-03-25 2021-09-29 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
KR20240014059A (ko) * 2021-05-27 2024-01-31 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 퀴놀린아민 화합물, 이의 제조 방법 및 약제에서의 이의 용도
EP4201948A1 (en) 2021-12-21 2023-06-28 Abivax Method of preparation of 1-(n-(quinolin-2-yl)-(phenylamino)-1-deoxy-beta-d-glucopyranuronic acid derivatives
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) * 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
WO2024109937A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物的可药用盐、晶型及其制备方法
WO2024109936A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
CN116617226B (zh) * 2023-06-21 2024-06-25 湖北工业大学 新型吲哚喹啉衍生物作为肠道病毒71型抑制剂的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
TR201910781T4 (tr) 2009-06-12 2019-08-21 Abivax Kanser tedavisi için yararlı bileşikler.
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
US9827237B2 (en) * 2013-07-05 2017-11-28 Abivax Compounds useful for treating diseases caused by retroviruses
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
CA2975577A1 (en) 2016-09-01
CN107531681A (zh) 2018-01-02
EP3059236A1 (en) 2016-08-24
JP6797126B2 (ja) 2020-12-09
HRP20200649T1 (hr) 2020-10-16
PT3262037T (pt) 2020-04-09
ES2785374T3 (es) 2020-10-06
HUE048577T2 (hu) 2020-07-28
EP3262037A1 (en) 2018-01-03
RS60369B1 (sr) 2020-07-31
RU2017128643A3 (es) 2019-04-15
CU24525B1 (es) 2021-06-08
RU2723013C2 (ru) 2020-06-08
PL3262037T3 (pl) 2020-10-19
CA2975577C (en) 2020-04-07
CU20170109A7 (es) 2018-02-08
CN107531681B (zh) 2020-11-24
SI3262037T1 (sl) 2020-09-30
BR112017017500A2 (pt) 2018-04-17
KR20170129698A (ko) 2017-11-27
US20180030078A1 (en) 2018-02-01
LT3262037T (lt) 2020-07-10
WO2016135052A1 (en) 2016-09-01
AU2016223687B2 (en) 2020-03-19
US10329317B2 (en) 2019-06-25
ZA201705633B (en) 2018-12-19
JP2018507215A (ja) 2018-03-15
AU2016223687A1 (en) 2017-08-31
KR102583506B1 (ko) 2023-09-26
BR112017017500B1 (pt) 2023-04-04
DK3262037T3 (da) 2020-05-04
EP3262037B1 (en) 2020-02-12
MX2017010506A (es) 2017-11-13
RU2017128643A (ru) 2019-03-25

Similar Documents

Publication Publication Date Title
MX381187B (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
NZ729150A (en) Antiretroviral agents
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
PH12015501881A1 (en) Amide compounds for the treatment of hiv
MD4754B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
UY35263A (es) Compuestos terapéuticos
EA201590862A1 (ru) Фармацевтические композиции
BR112017005917A2 (pt) processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana
MX384729B (es) Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2015198263A3 (en) Novel betulinic proline substituted derivatives as hiv inhibitors
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018002681A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?
EA033921B9 (ru) Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа
BR112018000179A2 (pt) composto, composição, e, método para tratar a infecção pelo hiv.
WO2015154883A8 (en) Neosoraphens